Government of the United States of America, as represented by the Secretary, Department of Health Patent applications |
Patent application number | Title | Published |
20130178692 | TRANSCRANIAL MAGNETIC STIMULATION SYSTEM AND METHODS - A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure. | 07-11-2013 |
20120065146 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament. | 03-15-2012 |
20110200987 | COMPOSITIONS AND METHODS FOR MODIFYING CELLULAR PROPERTIES - The invention generally provides compositions and methods for modulating cell properties and enhancing recombinant protein yields. In particular, the compositions and methods provide for cells having altered growth characteristics, including altered adhesion, rate of proliferation, growth to particular cell density, and recombinant protein expression level. | 08-18-2011 |
20090258036 | DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3' -UTR OF DENGUE TYPES 1, 2, 3, AND 4 OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1, 2, 3, AND 4 - The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4. | 10-15-2009 |